Dr. Sara Tolaney discusses the TroFuse-010 Trial, a phase 3 study evaluating Sacituzumab and combinations for metastatic HR+ breast cancer post-CDK4/6 inhibition, aiming to compare outcomes with standard chemotherapy.
2:20
0
